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Abstract
PURPOSE: Our preliminary report of imatinib mesylate (IM) in gastrointestinal stromal tumor (GIST) patients detailed
a high response rate; however, the long-term result is still unknown. We conducted an analysis of Taiwan advanced
inoperable/metastatic GIST patients treated on IM regarding survival, pattern of failure, potential prognostic factors,
andmutational status. PATIENTS ANDMETHODS: From 2001 to 2010, patients with pathologically proven advanced
inoperable/metastatic GIST receiving IM were enrolled onto this study. Data on KIT mutational status, measurable
tumor size, and other potential prognostic factors were prospectively collected. Patients were followed up for a
median of 33.6 months. RESULTS: There were 171 patients (106 men and 65 women) with response rate, and their
clinical benefit for IM was 57.3% and 87.1%, respectively. Median progression-free survival (PFS) and overall sur-
vival (OS) for these 171 patients are 37.6 and 71.0 months, respectively. Of 171 patients, 120 (70.2%) remained on
long-term IM use. Poor performance status, tumor larger than 11.5 cm, primary resistance, and the presence of an
exon 9 mutation were independently associated with unfavorable PFS. Regarding OS, poor performance status, pri-
mary resistance, and tumor larger than 11.5 cm were three independently unfavorable predictors. CONCLUSIONS:
Themedian PFS and OS of 171 GIST patients are 37.6 and 71.0 months, respectively. Poor performance status, tumor
size larger than 11.5 cm, primary resistance, and an exon 9 mutation were independently associated with unfavorable
PFS. Regarding OS, poor performance status, primary resistance, and tumor size larger than 11.5 cm were three
independent unfavorable predictors.
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Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesen-
chymal neoplasms of the gastrointestinal tract. In Taiwan, the annual
incidence of GIST is 13.74 per million Taiwanese [1]. Before 2001, no
effective systemic treatments existed for GISTs [2]. However, the as-
sociation between constitutively activated KIT and platelet-derived
growth factor receptor A (PDGFRA) signaling and GIST oncogenesis
provided justification for testing a small-molecule tyrosine kinase inhib-
itor in this tumor type [3]. Imatinib mesylate (IM) selectively inhibits
certain protein tyrosine kinases: intracellular ABL kinase, chimeric
BCR-ABL fusion oncoprotein of chronic myeloid leukemia, transmem-
brane receptor kit, and PDGFRs [4–7]. GISTs express the cell surface
transmembrane receptor kit with a tyrosine kinase activity. There are
frequent gain-of-function mutations of kit in GISTs [3]. These muta-
tions result in constitutive activation of kit signaling, which leads to
uncontrolled cell proliferation and resistance to apoptosis [3]. IM has
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shown a promising clinical result for an advanced GIST patient [8], and
several trials have shown a promising effect of this target therapy [6,9–11].
As shown in our previous preliminary study, Glivec had a significant
impact on survival in patients with advanced GISTs, but the follow-up
time is just 16 months and the patient number is limited [12].
This study represented a large single-institute experience on IM use
for a decade, including 171 patients with advanced GIST and followed
up to a median of 33.6 months. This study examined the long-term
impact of IM on patient response, survival, and the correlation of the
response rate with the kit gene mutation status. We also tried to eluci-
date the predictors for favorable PFS and OS of Taiwanese patients
with advanced and metastatic GIST receiving IM.
Materials and Methods
Patients, Study Design, and Efficacy Evaluation
From August 2001 to April 2010, 171 adult patients with histolog-
ically confirmed, advanced inoperable/metastatic GIST that expressed
the CD117 antigen (as a marker of the KIT receptor) and with mea-
surable disease based on Response Evaluation Criteria in Solid Tumors
(RECIST) [13] were eligible. Other eligibility criteria included an East-
ern Cooperative Oncology Group (ECOG) performance score of 3 or
less and adequate hematologic, renal, and hepatic function. A prospec-
tive, nonrandomized, single-center study was conducted to evaluate the
effect of IM in inducing an objective response or stable disease in
Taiwanese with advanced inoperable/metastatic GIST. Patients were
administered 400 mg of IM in 100-mg capsules, taken orally daily with
food. Patients had regular physical examinations and evaluations of per-
formance status, body weight, complete blood count, and serum chem-
istry. Standard computed tomography was performed on each patient
every 3 months for the first 3 years and every 6 months for the follow-
ing 2 years to assess the patient’s response. Tumor size was measured in
at least five target lesions with the sum of the largest dimension that was
used as a response evaluation indicator as described in RECIST [13].
Time to response (TTR = time point of best response − time point of
IM administration) was defined as the interval for best drug response
during imatinib treatment. Time to progression (TTP = time point of
disease progression − time point of IM administration) was defined as
the interval for worse drug response with disease progression during
imatinib treatment. Progression-free survival (PFS) is defined as no pro-
gression after administration of IM. Overall survival (OS) is defined as
survival after administration of IM and death as the end point of the
study or December 2010. Primary resistance is defined as PFS less than
6 months. Patients underwent regular physical examinations and eval-
uations of performance status, body weight, complete blood cell count,
and serum chemistry. The study was approved by the local institutional
review board of Chang Gung Memorial Hospital, and written informed
consent for drug administration and analysis of tumor-associated
genetic alteration was obtained independently from each patient.
Analysis of KIT and PDGFRA Mutations
Sections were prepared from formalin-fixed, paraffin-embedded pre-
treatment specimens trimmed to enrich tumor cells. Polymerase chain
reaction amplification of genomic DNA for KIT and PDGFRA was
sent to another hospital and performed by Professor C.Y. Tzen. Ampli-
fication was analyzed for mutations as previously described [14].
Statistical Analysis
Data were presented as percentages of patients or means with stan-
dard deviation. Numerical data were compared by an independent two-
sample t test. Pearson χ2 test and Fisher exact test were used for nominal
variables. Time-to-event analyses were performed using Kaplan-Meier
methods. The following potential prognostic variables were investigated
for their impact on long-term outcomes: age (<65 vs ≥65 years), sex,
ECOG performance status (score 0 or 1 vs 2 or 3), summed diameter of
five target tumor lesions (<11.5 vs≥11.5 cm), mutational status (exon 11
vs exon 9 vs wild type), response (complete response [CR] + partial
response [PR] vs stable disease [SD] vs progressive disease [PD]), and
categories of the following baseline laboratory values: white blood cells,
platelets, hemoglobin, albumin, liver function, and renal function. For
the prognostic factors evaluation, each potential candidate was initially
assessed by univariate analysis. Factors found significant at P < .05 were
included in a multivariate Cox proportional hazard model. Thereafter,
an enter-selection procedure was applied to select the most relevant
prognostic factors. Only factors that remained significant at the .05 level
during the selection procedure were included in the final model. All
statistical analyses were performed using SPSS computer software




Table 1 summarizes the demographic features of 171 patients with
advanced inoperable/metastatic GIST treated with IM. There were
Table 1. Demographic Data of the 171 Taiwanese Patients with GIST Receiving IM.
Age, median (range), y 58 (19-89)
Sex, M/F 106:65
Origin of GIST, n (%)
Stomach 60 (35.1)
Small bowel 76 (44.4)
Colon-rectum 19 (11.7)
Others 16 (9.4)
Tumor size before IM treatment, median (range), cm 10 (2.5-30)
Genetic spectrum of 122 patients tested, n (%)
Exon 11 mutation 90 (73.8)
Exon 9 mutation 21 (17.2)
PDGFRA (exon 18) 2 (1.6)
Wild type 9 (7.4)
Table 2. Antitumor Response of IM on 171 Taiwanese with Advanced GIST.
Response n (%) Median IM Administration Duration (Months) Median TTR/PFS (Months) Median Post-IM OS (Months)
CR 4 (2.3) 56.2 13.0/NA NA
PR 94 (55) 34.0 3.2/47.6 71.0
SD 51 (29.8) 29.1 3.9/42.7 80.6
PD 22 (12.9) 7.2 2.6* 17.3
*Means median time for time to progression.
Translational Oncology Vol. 4, No. 6, 2011 IM and GIST Expressing KIT: Taiwan Experience Yeh et al. 329
106 men and 65 women with a median age of 58 years old (range =
19-89 years old). The median tumor size before IM treatment
was 10.0 cm (range = 2.5-30.0 cm). Stomach was the most common
site for GISTs treated with IM (60/171, 35.1%), followed by jeju-
num (31/171, 18.1%), ileum (25/171, 14.6%), and duodenum (20/
171, 11.7%) (Table 1).
Treatment and Outcomes
Since 2001, in Taiwan, IM has been administered to patients with
advanced inoperable/metastatic GISTs. 400 mg IM per day was
given to all the 171 patients first. All of the 171 patients were fol-
lowed up after administration of IM at regular intervals until death or
until December 2010. Table 2 summarizes antitumor response of IM
on 171 Taiwanese with advanced inoperable/metastatic GIST. Over-
all, 4 patients (2.3%) had CR, 94 (55.0%) had PR, 51 had SD
(29.8%), and 22 had PD (12.9%). Of all GIST patients, 87.1%
had a clinical benefit. Among the 171 patients, the median TTR
for 4 patients who had CR was 13.0 months and that for 94 patients
who had PR was 3.2 months. The median PFS for the 94 PR and
51 SD patients was 47.6 and 42.7 months, respectively. The median
OS of the 94 PR and 51 SD patients was 71.0 and 80.6 months,
respectively. Whereas for the 22 PD patients, the median time to
progression was 2.6 months and the median OS was 17.3 months
(Table 2). Among the 22 GIST patients with primary resistance,
exon 9 is the most common cause (8 patients with exon 9 mutation),
followed by exon 11 mutation (6 patients with exon 11). Of 21 GIST
patients with exon 9 mutation, 8 (31%) developed primary resistance
after IM treatment, whereas of 90 GIST patients with exon 11 mutation,
6 (6.7%) developed primary resistance. Hence, patients with advanced
inoperable/metastatic GIST who harbored exon 9 mutation had a signif-
icantly higher chance of primary resistance when compared with those
who had exon 11 mutation (8/21 exon 9 vs 6/90 exon 11, P = .001).
Spectrum of Mutations in 171 Patients with Advanced
Inoperable/Metastatic GIST
Table 3 summarizes the correlation between antitumor response
and mutation status of 171 Taiwanese with advanced GIST treated
with IM. Tumor specimens suitable for genetic analysis were avail-
able from 122 (71.3%) of the 171 patients with advanced GIST.
Overall, 111 (90.9%) of the 122 examined GISTs had activated
mutations of kit exons 9 and 11. Nine (7.4%) had no mutation of
KIT, and only two patients with PDGFRAmutation (exon 18 V840).
Of 122 GISTs, 21 (17.2%) expressed exon 9 mutation and 90 (73.8%)
had exon 11 mutation. In 90 patients with GISTs harboring kit exon
11 mutations, the CR and PR rates (overall response rate = 74.4% [4 CR
and 63 PR]) are significantly higher than those of 9 of 21 patients with
tumors containing a kit exon 9 mutation (overall response rate = 40.9%
[9 PR]) (P = .0005; Table 3). Regarding clinical benefit, GIST patients
harboring kit 11 mutations also had a significantly higher clinical
benefit than those harboring kit 9 mutations (P = .0005).
Survival Analysis for 171 Patients with Advanced
Inoperable/Metastatic GIST Receiving Imatinib
The median follow-up period after IM was 33.6 months (range =
1.6-110.9 months). Of these 171 patients, 87 developed progression
(50.9%) and 51 (29.8%) died because of GIST. The 171 Taiwanese
with advanced inoperable/metastatic GIST had a median PFS of
37.64 months and OS of 71.0 months (Figures 1 and 2). Tables 4
and 5 summarize the survival analysis of PFS and OS of these 171
GIST patients after IM treatment, including clinical features, tumor
size, mutational status, and laboratory data. Univariate survival analysis
revealed that age older than 65 years, poor performance with ECOG 2
or 3, exon 9 mutation, tumor size larger than 11.5 cm, and primary
resistance are associated with inferior PFS of GIST patients receiving
Table 3. Correlation between Antitumor Response and Mutation Status of 171 Taiwanese with
Advanced GIST Treated with IM.
CR PR SD PD P
Exon 9 (n = 21) 0 9 (42.9%) 4 (19.0%) 8 (30.1%) .0005
Exon 11 (n = 90) 4 (4.4%) 63 (70%) 17 (18.9%) 6 (6.7%)
Wild type (n = 9) 0 2 (22.2%) 5 (55.6%) 2 (22.2%)
CR + PR + SD PD P
Exon 9 (n = 21) 13 (61.9%) 8 (30.1%) .0005
Exon 11 (n = 90) 84 (93.3%) 6 (6.7%)
Wild type (n = 9) 7 (77.8%) 2 (22.2%)
Figure 1. PFS of 171 Taiwanesewith advanced GIST treated with IM.
Figure 2. OS of 171 Taiwanese with advanced GIST treated with IM.
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Table 4. Prognostic Factors for PFS Based on Univariate Analyses and Final Multivariate Model.
Factors Univariate Analysis Multivariate Analysis
Total No. No. Events 5-Year PFS (%) Cumulative Hazard Ratio Log-rank, P P Hazard Ratio (95% CI)
Age, y
≤65 124 61 44.86 1 1
>65 47 26 13.26 2.52 .049 .471 1.24 (0.70-2.19)
Sex
Male 106 54 37.84 1
Female 65 33 38.33 0.99 .981
ECOG
0, 1 139 65 42.77 1 1
2, 3 32 22 12.23 2.47 .0002 .048 1.93 (1.02-4.07)
Genetic status
Exon 9 22 18 18.70 1 1
Exon 11 94 50 34.18 0.64 .042 0.52 (0.28-0.98)
Wild type 13 4 64.10 0.27 .003 .036 0.29 (0.09-0.92)
Sum of tumor, cm
<11.5 77 32 41.18 1 1
≥11.5 80 48 32.67 1.26 .043 .004 2.18 (1.29-3.69)
WBC, ×109/L
<10 136 70 38.30 1
≥10 19 10 24.56 1.46 .706
RBC, ×109/L
<4.0 58 32 28.61 1
≥4.0 76 40 30.91 0.94 .915
Hemoglobin, g/dl
<12 93 50 31.17 1
≥12 61 29 41.03 0.76 .328
HCT, %
<36 71 41 23.79 1
≥36 64 32 36.64 0.70 .391
MCV, f l
<80 23 11 29.11 1
≥80 111 61 29.67 0.98 .792
Platelet, ×109/L
<150 19 10 33.39 1
≥150 136 70 34.99 0.96 .922
Albumin, g/dl
<3.5 35 20 35.56 1
≥3.5 79 38 34.36 1.03 .316
INR
≤1.2 70 38 20.94 1
>1.2 10 6 35.00 0.67 .832
BUN, mg/dl
≤21 110 58 30.32 1
>21 14 8 40.41 0.76 .820
Creatinine, mg/dl
≤1.03 99 54 32.69 1
>1.03 52 25 37.34 0.88 .239
AST, U/L
<34 114 56 37.50 1
≥34 27 15 32.75 1.14 .563
ALT, U/L
<36 115 59 32.04 1
≥36 22 13 34.34 0.94 .245
ALK-P, U/L
<94 98 45 39.95 1
≥94 26 17 31.33 1.27 .310
Bil, T
<1.0 94 49 37.72 1
≥1.0 25 10 34.52 1.09 .458
Sodium, mEq/L
<139 55 32 23.13 1
>139 48 24 43.80 0.56 .818
Potassium, mEq/L
≤4 58 32 25.60 1
>4 45 24 33.15 0.81 .819
Response
CR/PR 98 41 44.53 1 1
SD 51 24 41.91 1.07 .083 1.75 (0.93-3.29)
PD 22 22 0.00 NA <.0001 <.0001 186.88 (37.15-940.09)
95% CI indicates 95% confidence interval; ALK-P, alkaline phosphatase; ALT, alanine ainotransferase; AST, aspartate aminotransferase; Bil, T, total bilirubin; BUN, blood urea nitrogen; CR, complete
response; ECOG, Eastern Cooperative Oncology Group; HCT, hematocrit; INR, international normalized ratio; PD, progressive disease; PFS, progression free survival; PR, partial response; SD, stable
disease; y, years.
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IM treatment (Figure 3). Multivariate Cox proportional hazard analysis
demonstrated that poor performance status, exon 9mutation, tumor size
larger than 11.5 cm, and primary resistance are associated with an in-
ferior PFS of GIST patients receiving IM treatment. Regarding OS,
univariate survival analysis revealed that age older than 65 years, poor
performance with ECOG 2 or 3, poor nutritional status, and tumor size
larger than 11.5 cm are associated with inferior OS of GIST patients
receiving IM treatment (Figure 4). However, multivariate Cox propor-
tional hazard analysis demonstrated that good performance status, tumor
size less than 11.5 cm, and good response were the only three inde-
pendent prognostic factors that favorably affected OS of patients with
advanced inoperable/metastatic GIST after IM treatment (Table 5).
Discussion
This is one of the largest series in a single center that dealt with patients
with advanced inoperable/metastatic GIST treated with IM for a decade.
Several issues of interest emerged with the longer follow-up of Taiwanese
patients with advanced inoperable/metastatic GIST on this study.
First, IM, a semiselective inhibitor of uncontrolled kinase activity
of KIT and PDGFRA, can control advanced GIST in a large pro-
portion of patients for more than 5 years. The 171 Taiwanese pa-
tients with advanced inoperable/metastatic GIST had a median PFS of
37.64 months and OS of 71.0 months after a median follow-up of up
to 33.6 months. Of 171 patients, 87 (50.9%) developed progression
and 51 (29.8%) died because of GIST. These results are substantially
superior to the B2222 study [11] but similar to reports on Poland [15]
and Korea [16] (median PFS was 40.5 and 48.0 months, respectively).
Because a substantial fraction of patients (87/171, 50.9%) on this study
eventually faced disease progression, this finding may imply that salvage
therapy (potentially including increased imatinib doses [17], alternative
tyrosine kinase inhibitors [18], or surgery [19]) is effective. Multimo-
dality therapy is paramount for progression of GIST after IM treatment
and to delay of death from GIST.
Figure 3. PFS of 171 Taiwanese with advanced GIST treated with IM in ECOG performance status (A), tumor size (B), mutation status (C),
and response (D).
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Second, similar to the B2222 study, long-term PFS and OS on IM
were equivalent between patients with GIST achieving an objective
response and even complete response by RECIST and those whose
disease merely stabilized [11]. This study showed that the most de-
finitive unfavorable factor for PFS and OS of patients with advanced
inoperable/metastatic GIST is primary resistance. The reason for pri-
mary resistance as the most definitive unfavorable factor for PFS is ob-
vious because primary resistance is defined as PFS of less than 6 months.
However, it is still of note that the estimated median OS of patients with
primary resistance was quite short (17.3 months), which suggests that
salvage therapy for this population is less effective and/or that the mech-
anisms of resistance to tyrosine kinase inhibition between this popula-
tion and those with secondary imatinib resistance are quite different.
Third, tumor size assessments based on RECIST demonstrated
that tumor size is the other important predictor for PFS as well as
OS in this study. Although response assessment systems using density
and/or smaller changes in size are much more precise [20], it is likely
that they would yield information on potential responses more quickly.
Different from the B2222 study, tumor bulk was represented by
quantifying five measurable largest lesions as depicted by RECIST
[13]. Similar to the B2222 study, patients with the bulkiest tumors
had significantly inferior PFS and OS compared to those who had
smaller tumors. This supported the hypothesis that a larger number of
tumor cells should be quantitatively proportional to a greater likelihood
of harboring more resistant clones.
Fourth, similar to the B2222 study, our study showed that perfor-
mance status and mutational status are independently associated with
PFS [11]. Exon 9 mutation had the poorest PFS after IM treatment.
Only performance status is also independently associated with OS in
this study. Contrary to the B2222 study, this study did not show that
sex, neutrophil count, albumin level, as well as other laboratory data
were independently associated with either PFS or OS.
Finally, GISTs particularly present a variety of genomic mutations
across two different receptor tyrosine kinase genes. KIT or PDGFRA
mutation in Taiwanese patients with clinically advanced inoperable/
metastatic GIST was examined in this study. In response rate for IM,
similar to our previous report, IM induced a sustained objective response
in more than half of the Taiwanese patients with advanced GISTs
Figure 4. OS of 171 Taiwanese with advanced GIST treated with IM in ECOG performance status (A), tumor size (B), and response (C).
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Table 5. Prognostic Factors for OS Based on Univariate Analyses and Final Multivariate Model.
Factors Univariate Analysis Multivariate Analysis
Total No. No. Events 5-Year PFS (%) Cumulative Hazard Ratio Log-rank, P P Hazard Ratio (95% CI)
Age, y
≤65 124 33 65.50 1 1
>65 47 18 49.43 1.67 .024 .531 0.72 (0.26-2.02)
Sex
Male 106 32 62.39 1
Female 65 19 61.94 1.02 .840
ECOG
0, 1 139 33 71.50 1 1
2, 3 32 18 19.39 4.89 <.0001 <.001 5.17 (2.10-12.75)
Genetic status
Exon 9 22 8 50.59 1
Exon 11 94 32 65.70 0.62
Wild type 13 2 70.00 0.85 .557
Sum of tumor, cm
<11.5 77 15 72.71 1 1
≥11.5 80 30 52.88 2.00 .012 .027 3.21 (1.14-9.04)
WBC, ×109/L
<10 136 39 58.34 1
≥10 19 6 81.16 0.39 .906
RBC, ×109/L
<4.0 58 22 51.97 1
≥4.0 76 20 63.47 0.69 .177
Hemoglobin, g/dl
<12 93 31 50.48 1 1
≥12 61 14 75.30 0.42 .054 .157 0.29 (0.05-1.62)
HCT, %
<36 71 26 46.67 1 1
≥36 64 16 72.89 0.41 .072 .729 1.31 (0.29-6.01)
MCV, f l
<80 23 8 49.90 1
≥80 111 34 61.19 0.71 .685
Platelet, ×109/L
<150 19 6 73.0 1
≥150 136 39 59.3 1.66 .938
Albumin, g/dl
<3.5 35 14 45.10 1 1
≥3.5 79 17 60.82 0.62 .049 .370 0.67 (0.28-1.60)
INR
≤1.2 70 20 60.14 1
>1.2 10 3 63.00 0.91 .896
BUN, mg/dl
≤21 110 30 63.55 1
>21 14 6 38.69 2.09 .261
Creatinine, mg/dl
≤1.03 99 29 53.99 1
>1.03 52 15 71.61 0.54 .542
AST, U/L
<34 114 30 59.52 1
≥34 27 9 62.36 0.91 .610
ALT, U/L
<36 115 35 59.75 1
≥36 22 5 67.03 0.78 .664
ALK-P, U/L
<94 98 25 58.66 1
≥94 26 8 59.33 0.98 0.634
Bil, T
<1.0 94 24 60.47 1
≥1.0 25 7 44.33 1.62 0.741
Sodium, mEq/L
<139 55 22 58.22 1
>139 48 10 63.95 0.83 0.179
Potassium, mEq/L
≤4 58 22 54.35 1
>4 45 10 71.90 0.54 0.244
Response
CR/PR 98 25 66.53 1 1
SD 51 12 68.69 0.92 .160 2.12 (0.75-5.97)
PD 22 14 24.62 1.40 <0.0001 <.0001 17.65 (5.21-59.87)
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(96/171, 57.3%). Gain-of-function mutations of PDGFRA were
only recently discovered in GISTs [21], and studies have reported
that PDGFRA and kit mutations are mutually exclusive [14]. How-
ever, the incidence of PDGFR mutation in Taiwanese patients with
advanced inoperable/metastatic GIST is very low (1.6%) compared
with series from the west. Racial difference may be the reason for the
difference in genetic alteration between the west and Taiwanese
patients. A subset of GIST tumors in this study lacked detectable
kit or PDGFRA mutations. Although such GISTs lack apparent
genomic mutations, they can express phosphorylated kit or PDGFRA
proteins that likely contribute to tumor proliferation or survival [14].
Contrary to the observation of Heinrich et al. [22], GISTs lacking a
detectable kinase mutation had a similar clinical benefit for imatinib
to tumor with an exon 11 mutation or an exon 9 mutation (77.8% vs
93.9% and 77.8% vs 61.9%, P = .154 and P = .675, respectively). Re-
garding the relationship between response rate and kinase mutation, kit
exon 11 and exon 9 mutations predict a favorable response to IM. In
this study, activated mutations of kit exons 11 and 9 are found in most
patients (90.9%) with GIST. Similar to the study of Heinrich et al.
[22], the clinical benefit did differ between the groups of patients whose
GISTs had KIT exons 9 and 11 mutation (61.9% vs 93.3%, P = .0005).
This observation confirmed metaGIST that the KIT oncoproteins en-
coded by exon 9 should be escalated to a higher dose of IM, although
the number of cases is still limited.
In conclusion, the median PFS and OS of or 171 GIST patients
are 37.6 and 71.0 months. Poor performance status, tumor size larger
than 11.5 cm, primary resistance, and an exon 9 mutation were inde-
pendently associated with an unfavorable PFS. Regarding OS, poor
performance status, primary resistance, and tumor size larger than
11.5 cm were three independent unfavorable predictors.
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